MAS Consultations

Key dates

2026-11-02

MAS announced the grant scheme, commenced Consultation Paper P018-2026, and the Infrastructure Capability Development Grant took effect.

2026-12-18 Deadline

Deadline for comments on MAS Consultation Paper P018-2026 concerning capital treatment for securitisation and infrastructure investments under RBC 2.

2026-03-31

Earlier RBC 2 revisions concerning differentiated capital treatment for qualifying infrastructure investments took effect; this is relevant background to the current consultation.

Suggested considerations

• Compliance and regulatory affairs teams should review Consultation Paper P018-2026 and consider submitting comments to MAS by 18 December 2026.
• Insurers should distinguish the currently effective RBC 2 requirements from the proposed capital treatments and avoid applying the proposed lower charges before the relevant amendments take effect.
• Investment, risk and actuarial teams should inventory infrastructure debt, infrastructure equity and securitisation exposures and assess which assets could potentially satisfy the proposed credit-quality, contractual-revenue, demand-risk, counterparty, securitisation, diversification and liquidity criteria.
• Firms should review their investment due-diligence, valuation, credit-assessment and documentation processes so that qualifying characteristics can be evidenced and maintained throughout the investment lifecycle.
• Insurers considering the grant should contact MAS to obtain the Infrastructure Capability Development Grant terms, eligibility requirements, application process, eligible-cost rules and reporting conditions.
• Firms should monitor MAS updates on standardised disclosure templates, assessment guidance and fund-manager declarations and assess whether investment mandates and manager reporting can support those formats.
• Insurers should monitor MAS recognition of additional external credit assessment institutions and review whether expanded recognised-rating coverage could affect sourcing, eligibility or capital calculations.
• Governance committees should consider whether proposed infrastructure allocations remain consistent with policyholder protection, asset-liability management, concentration limits, liquidity needs and existing investment-risk policies.

What changed

The Infrastructure Capability Development Grant takes effect on 2 November 2026 and will be funded through the Financial Sector Development Fund. It may support dedicated investment teams, staff capability development, and professional services used to establish or expand infrastructure investment activities in Singapore; insurers must approach MAS for scheme details and eligibility conditions. MAS is consulting on further amendments to the insurance capital framework under RBC 2.

Key dates

2026-11-02

MAS published Circular ID 12/26 and opened consultation P018-2026 on capital treatment for securitisation and infrastructure investments under RBC 2.

2026-11-02

The S$30 million Infrastructure Capability Development Grant for Insurers took effect, subject to MAS grant arrangements.

2026-12-18 Deadline

Deadline for submitting comments on consultation P018-2026.

2026-03-31

Earlier finalised RBC 2 revisions to the capital treatment of securitisation and infrastructure investments took effect; the current consultation proposes further refinements to that framework.

Suggested considerations

• Compliance and capital teams should review the consultation paper and consider submitting comments to MAS by 18 December 2026, particularly on eligibility tests, evidence requirements, capital calibrations and implementation timing.
• Firms should map current and planned infrastructure debt, infrastructure equity, infrastructure-fund and securitisation exposures against the proposed qualifying criteria, distinguishing assets that could benefit from lower charges from assets that would remain subject to existing treatment.
• Investment, risk and finance functions should assess whether existing due diligence, valuation, credit assessment, look-through analysis and documentation can evidence contractual revenues, demand-risk limitations, counterparty strength, tranche seniority, investment grade status, diversification, liquidity and simplicity, transparency and comparability.
• Firms should monitor amendments to MAS Notice 133 and Notice FHC-N133 and avoid reflecting proposed capital relief in regulatory capital planning, pricing or investment limits until the proposals are finalised and effective.
• Insurers may wish to assess whether they qualify for or could benefit from the Infrastructure Capability Development Grant and identify capability gaps in origination, underwriting, infrastructure valuation, credit analysis and ongoing monitoring.
• Governance teams should establish a process for monitoring the additional external credit assessment institutions, standardised disclosure templates, fund-manager declarations and assessment guidance that MAS may introduce.
• Groups with infrastructure investments held through funds or structured products should confirm whether the final treatment will permit look-through and should not assume that infrastructure-backed structured products qualify for infrastructure treatment rather than structured-product treatment.

What changed

This is a consultation and does not itself amend Notice 133 or impose new binding capital requirements. MAS is proposing lower capital charges for rated infrastructure debt that satisfies specified credit-quality and other qualifying criteria; for qualifying infrastructure equity and debt investments with risk mitigants such as long-term contractual or regulated revenues, limited demand-risk exposure and strong counterparties; and for senior investment-grade securitisation tranches meeting relevant simplicity, transparency and comparability criteria or specified diversification and liquidity...

Key dates

07 July 2026

- MAS publishes Circular ID 08/26 and Consultation Paper P013-2026 on the Proposed Framework for Protected Cell Companies in Singapore, opening the consultation

07 August 2026

- Closing date for submissions to MAS on the PCC consultation paper

Suggested considerations

• Review the MAS Consultation Paper P013-2026 in detail and map proposed PCC requirements against your current and planned captive, reinsurance, ILS and sovereign risk pool structures.
• Conduct an internal impact assessment on how PCC introduction would affect corporate structuring, capital allocation, risk management, and policyholder/investor protections within your group.
• Identify potential use cases for PCCs (e.g. multi‑cell captives, collateralised reinsurance platforms, ILS issuance vehicles, sovereign risk pools) and assess legal, tax, accounting and regulatory implications for each use case.
• Engage legal, compliance, actuarial and treasury functions to develop a coordinated response to MAS addressing prudential treatment, segregation mechanics, governance expectations and disclosure considerations for PCCs.
• Prepare and submit detailed consultation feedback to MAS by 07 August 2026, including any requested clarifications, suggested safeguards, or recommended scope limitations or expansions for PCC usage.

What changed

• - MAS proposes introducing a Protected Cell Company (PCC) as a new corporate structure comprising a single legal entity with assets and liabilities statutorily segregated into distinct cells within...
• The PCC structure is intended to be available only to MAS-licensed entities engaged in captive insurance, insurance‑linked securities (ILS) and sovereign risk pooling activities, not generally to all...
• Each PCC will have a core and multiple cells, with ring‑fencing of assets and liabilities such that creditors of one cell should not have recourse to assets of other cells or the core, subject to...
• The framework is positioned to enable multiple risk issuances and programs within one vehicle, improving cost and operational efficiency compared with establishing multiple standalone insurers or...
• MAS signals that the PCC framework will complement existing special purpose reinsurance and alternative risk‑transfer structures, and is conceptually aligned with Singapore’s broader approach to...

Key dates

1 January 2024

- Effective date of baseline Notice FHC-N133 (pre-amendment)

24 July 2025

- Issuance of Consultation Paper P011-2025 on Proposed Changes to the Group Capital Framework

25 August 2025

- Consultation closing date (now passed as of February 2026)

Suggested considerations

• Gap analysis: Model impacts on group financial resources, identify data/ system gaps for NIE/JV risk assessments, and simulate capital shortfalls under new limits.
• Stakeholder engagement: If not already done, firms that submitted feedback by 25 August 2025 should track MAS response; prepare internal policy updates and board reporting on potential capital adjustments.
• Ongoing: Enhance monitoring of non-insurance subsidiaries and JVs; update valuation processes to align with RBC 2 consolidation once finalized.

What changed

• The proposals target refinements to the group capital framework in Notice FHC-N133 (effective 1 January 2024) and include:
• Risk charging approach for non-insurance entities (NIEs): Introduce a standardized method to assess and charge capital for risks posed by NIEs within the DFHC group, with potential additional charges...
• Enhanced capital treatment for joint ventures (JVs): Strengthen requirements to better reflect JV risks in group capital computations.
• Limit on recognition of capital from non-controlling interests (NCIs): Cap the amount of NCI capital recognized in group financial resources to account for its non-fungible nature (currently, NCI...